An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We evaluated nonpsychotic behavioral adverse events (BAEs) in patients receiving levetiracetam (LEV) who switched to brivaracetam (BRV). Patients ≥16 years of age, receiving 2-3 antiepileptic drugs (AEDs), including LEV 1-3g/day, and experiencing BAEs within 16 weeks of LEV treatment initiation, enrolled in an open-label Phase 3b study (NCT01653262) comprising a ≤1-week screening period, an immediate switch from LEV to BRV 200mg/day (without titration), and a 12-week treatment period. The percentages of patients with investigator-assessed clinically meaningful reduction in BAEs, shift in maximum BAE intensity, and change in health-related quality of life (HRQoL) (Patient-Weighted Quality of Life in Epilepsy Inventory-Form 31 [QOLIE-31-P]) were assessed. Of 29 patients enrolled, 26 (89.7%) completed the study. At the end of the treatment period, 27/29 (93.1%) patients switched to BRV had clinically meaningful reductions in BAEs. Physicians reported a reduction in the maximum intensity of primary BAEs in 27/29 (93.1%) patients. Mean change from baseline to Week 12 in QOLIE-31-P total score was 12.1, indicating improved HRQoL. During the treatment period, 23/29 (79.3%) patients reported treatment-emergent adverse events (TEAEs). One patient reported a serious TEAE (suicidal ideation and suicide attempt). Two patients discontinued BRV because of TEAEs. Findings from this small study suggest that patients experiencing BAEs associated with LEV may benefit from switching to BRV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cited by
Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy
Chen, B., Choi, H., Hirsch, L. J., Katz, A., Legge, A., Buchsbaum, R., & Detyniecki, K. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.08.039 · Cited by 399
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
“The more selective SV2A mechanism of brivaracetam versus levetiracetam triggered UCB to perform a small, open-label study to assess if brivaracetam may be associated with fewer behavioral adverse effects [111].”
BackgroundKlitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99
A review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
“An exploratory, prospective, Phase IIIB open-label study was conducted in 29 adults with epilepsy who had experienced seizure control on LEV but had disabling nonpsychotic behavioral AEs (NCT01653262).(101) Patients were switched abruptly from their last full dose of LEV (1–3 g/ day) to BRV target dose 200 mg/day with…”
MethodKlein, P., & Bourikas, D. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02876-z · Cited by 21
“…open-label trial (N01395; NCT01653262) in patients receiving LEV who switched to BRV (50–200 mg/day) because of non-psychotic BAEs, 93.1% of patients had clinically meaningful reductions in BAEs, suggesting that patients who experience BAEs with LEV treatment may benefit from a switch to BRV [65].”
BackgroundInfluentialPresynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13
“The results of observational studies suggest that this change can be done overnight without fearing new side effects development or deterioration of the previ - ously experienced side effects [ 102, 103, 107].”
Background
Metadata
- Authors
- Yates, S. L., Fakhoury, T., Liang, W., Eckhardt, K., Borghs, S., & D'Souza, J.
- Venue
- Epilepsy & Behavior
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 52
- Issue
- Pt A
- Pages
- 165-168
- ISSN
- 1525-5050 (ISSN-L)
- OpenAlex
- W2099690974
- Cited by
- 155
- References
- 1
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.